

Financial Tear Sheet

Corporate Profile

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company owns a significant intellectual property (IP) portfolio related to DMF formulations. The Company granted to Biogen an irrevocable license to all of its IP through the recent License Agreement and received from Biogen a non-refundable cash fee of \$1.25 billion in February 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 opposition proceeding.

Stock Performance

FWP (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price **\$5.60**

Change (%) ▼ 0.2 (3.45%)

Volume 7,239

52 Week Low \$2.70

Market Cap \$273,434,556

Rolling EPS -0.71

PE Ratio 0

Shares Outstanding 47,143,889

Data as of 09/25/17 10:43 a.m. ET



Recent Headlines

09/05/17

Forward Pharma Files Opening Brief in the Appeal of the U.S. Patent Interference to the Federal Circuit

09/01/17

Forward Pharma Board of Directors Approves Capital Reduction and Returns EUR 917.7 Million to Shareholders

08/02/17

Forward Pharma Obtains Shareholder Approval of the Planned Capital Reduction at the Extraordinary General Meeting

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
09/11/17	6-K
09/05/17	6-K
09/01/17	6-K
09/01/17	6-K

Corporate Governance

Claus Bo Svendsen, MD, PhD	CEO
Peder Møller Andersen, MD	COO

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources